BIRC5 and malignant glioma: As described earlier, allogeneic BM-hMSCs and NSCs are being used to carry the oncolytic adenoviruses, DNX-2401 (NCT03896568) and CRAd-Survivin-pk7 (NCT03072134) in two different clinical trials in malignant glioma patients.